Company Overview of C4 Therapeutics, Inc.
C4 Therapeutics, Inc. develops targeted protein degradation therapeutics for the treatment of various diseases. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin/proteasome system. C4 Therapeutics, Inc. has strategic collaborations with Roche Pharma and Calico Life Sciences LLC. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
675 West Kendall Street
Cambridge, MA 02142
Founded in 2015
Key Executives for C4 Therapeutics, Inc.
C4 Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact C4 Therapeutics, Inc., please visit c4therapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.